Egetis Therapeutics AB (publ)
STO: EGTX.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicklas Westerholm
- Employees
- 38
- Headquarters
- Stockholm, Sweden
- IPO year
- 2011
- Market cap
- SEK 2.6B
- Website
- https://www.egetis.com
Loading EGTX…
Loading profile data…Frequently asked questions about EGTX
What does Egetis Therapeutics AB (publ) (EGTX.ST) do?
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracet...
Where does EGTX.ST trade?
Egetis Therapeutics AB (publ) (EGTX.ST) trades on the Stockholm Stock Exchange.
What sector is EGTX.ST in?
Egetis Therapeutics AB (publ) (EGTX.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Egetis Therapeutics AB (publ)?
Nicklas Westerholm is the chief executive officer of Egetis Therapeutics AB (publ) (EGTX.ST).
Where is Egetis Therapeutics AB (publ) headquartered?
Egetis Therapeutics AB (publ) is headquartered in Sweden.
Does EGTX.ST pay a dividend?
Egetis Therapeutics AB (publ) (EGTX.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EGTX.ST go public?
Egetis Therapeutics AB (publ) (EGTX.ST) completed its initial public offering in 2011.